AJP - GI Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol 293: G1114-G1123, 2007. First published August 30, 2007; doi:10.1152/ajpgi.00026.2007
0193-1857/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/6/G1114    most recent
00026.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoshida, Y.
Right arrow Articles by Fujimoto, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshida, Y.
Right arrow Articles by Fujimoto, J.

LIVER AND BILIARY TRACT

Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease

Yasuhiko Yoshida,1 Tadamichi Hirano,1 Gakuhei Son,1 Yuji Iimuro,1 Takehito Imado,2 Tsuyoshi Iwasaki,2 and Jiro Fujimoto1

1First Department of Surgery, and 2Division of Rheumatology and Clinical Immunology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

Submitted 12 January 2007 ; accepted in final form 30 August 2007

Allogeneic bone-marrow transplantation (BMT) can induce a powerful graft-vs.-tumor (GVT) effect not only on hematological malignancies but also on solid tumors. However, graft-vs.-host disease (GVHD) is a major complication of allogeneic BMT. We assessed GVT effect on hepatocellular carcinoma (HCC) and the effects of hepatocyte growth factor (HGF) gene transduction on GVHD in HCC transplanted mice. (C57BL/6 x C3H/HeJ)F1(B6C3F1, H-2bxk) mice were used as recipients and C3H/HeJ(H-2k) mice were used as donors. Hepa1-a (a C57L mouse-derived hepatoma cell, H-2b) was subcutaneously injected into the recipient mice. Tumor bearing mice were treated in the following ways: group 1, no treatment; group 2, total body irradiation (TBI); group 3, TBI and BMT; group 4, TBI and BMT with empty vector; group 5, TBI and BMT with HGF gene transduction; group 6, TBI and BMT with administration of FK506, a representative immunosuppressive agent. Acute GVHD was assessed by histological examination of the liver, small intestines, and large intestines. Tumor growth was markedly suppressed in mice that received an allogeneic BMT. Donor-derived CD8+ T cells had infiltrated into the tumor, and cytotoxic CD8+ T cells against HCC were present. However, among the four groups that received a BMT, this suppressive effect was weaker in group 6 compared with the other three groups (groups 3, 4, and 5). HGF gene transduction improved GVHD while preserving the GVT effects. Allogeneic BMT markedly suppresses the growth of HCC. Simultaneous HGF gene transfer can suppress GVHD while preserving the GVT effect.

hepatocellular carcinoma; bone marrow transplantation; graft versus tumor; graft-versus-host disease; hepatocyte growth factor



Address for reprint requests and other correspondence: J. Fujimoto, First Dept. of Surgery, Hyogo College of Medicine, Mukogawacho, Nishinomiya, 663, Japan (e-mail: sfujimo{at}hyo-med.ac.jp)




This article has been cited by other articles:


Home page
Stem CellsHome page
A. Banas, T. Teratani, Y. Yamamoto, M. Tokuhara, F. Takeshita, M. Osaki, M. Kawamata, T. Kato, H. Okochi, and T. Ochiya
IFATS Collection: In Vivo Therapeutic Potential of Human Adipose Tissue Mesenchymal Stem Cells After Transplantation into Mice with Liver Injury
Stem Cells, October 1, 2008; 26(10): 2705 - 2712.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.